Herceptin
Trastuzumab
- Strength
- 150 mg/7.4mL
- Form
- Injection, Powder, Lyophilized, For Solution
- Class
- HER2/neu Receptor Antagonist
Genentech, Inc.
Not stocked by us — reference only
trastuzumab-dkst
Listed by Biocon Biologics Inc.
| Dosage form | Injection, Powder, Lyophilized, For Solution |
|---|---|
| Route | Intravenous |
| Drug class | HER2/neu Receptor Antagonist |
| Approval route | BLA — biologic licence |
| NDC code | 83257-003 |
| FDA application | BLA761074 |
| RxNorm concept | 2179753 |
| Marketed since | October 2023 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Trastuzumab
Genentech, Inc.
Not stocked by us — reference only
Trastuzumab and hyaluronidase-oysk
Genentech, Inc.
Not stocked by us — reference only
TRASTUZUMAB
Cephalon, Inc.
Not stocked by us — reference only
trastuzumab-anns
Amgen, Inc
Not stocked by us — reference only
trastuzumab-anns
Amgen, Inc
Not stocked by us — reference only
trastuzumab
Mylan Institutional LLC
Not stocked by us — reference only
trastuzumab-dkst
Biocon Biologics Inc.
Not stocked by us — reference only
trastuzumab
Organon LLC
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.